Last reviewed · How we verify
Racemate Praziquantel ODT
At a glance
| Generic name | Racemate Praziquantel ODT |
|---|---|
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- L-PZQ ODT in Schistosoma Infected Children (PHASE3)
- An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni) (PHASE2)
- Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Racemate Praziquantel ODT CI brief — competitive landscape report
- Racemate Praziquantel ODT updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI